Navigation Links
Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Date:11/26/2013

SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at two investor conferences next week.  

On December 3 at 2:15pm Eastern Time (11:15am Pacific Time) he will make a presentation at the Deutsche Bank 2013 Biofest in Boston. 

On December 4 at 11:30am Eastern Time (8:30am Pacific Time) he will make a presentation at the 25th Annual Piper Jaffray Healthcare Conference in New York City. 

Both webcasts may be accessed live on the Company's website at http://www.neurocrine.com. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentations will be available on the website approximately one hour after the conclusion of each event and will be archived for one month.

Neurocrine Biosciences, Inc. is a clinical stage drug discovery company primarily focused on neurological and endocrine based diseases and disorders. The Company discovers and develops innovative pharmaceuticals, in diseases with high unmet medical needs or where the existing drug classes are inadequate, through a disciplined yet entrepreneurial process. Utilizing a portfolio approach to drug discovery, Neurocrine has multiple small molecule drug candidates at various stages of pharmaceutical development. Neurocrine's two lead late stage clinical programs are elagolix, a GnRH antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned VMAT2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2013 Results
2. Neurocrine Biosciences Reports Second Quarter 2013 Results
3. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
4. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
5. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
6. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
7. Neurocrine Biosciences Reports Third Quarter 2012 Results
8. Neurocrine Biosciences Reports Second Quarter 2012 Results
9. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
10. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 A person commits a crime, and the ... track the criminal down. An outbreak of foodborne ... Administration (FDA) uses DNA evidence to track down the bacteria ... far-fetched? It,s not. The FDA has increasingly used a complex, ... foodborne illnesses. Put as simply as possible, whole genome sequencing ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
Breaking Biology News(10 mins):